Tryptamine Therapeutics Limited (ASX:TYP)

Tryptamine Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	-7.37	-5.85	-8.35	-8.94	-0.48
Depreciation & Amortization	0.01	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	1.04	-
Stock-Based Compensation	1.8	0.4	0.64	2.81	0.21
Other Operating Activities	1.24	0.22	-	-	0.02
Change in Accounts Receivable	-	-	0.02	-0.02	-
Change in Accounts Payable	-0.76	0.86	1.12	-0	0.2
Change in Other Net Operating Assets	-2.12	0.34	0.09	-0.37	-
Operating Cash Flow	-7.2	-4.03	-6.47	-5.48	-0.04
Cash Acquisitions	2.02	-	-	-	-
Sale (Purchase) of Intangibles	-	-0.01	-0.15	-0.03	-0
Investing Cash Flow	2.02	-0.01	-0.15	-0.03	-0
Total Debt Issued	-	-	-	-	0.01
Short-Term Debt Repaid	-	-	-	-0	-
Total Debt Repaid	-	-	-	-0	-
Net Debt Issued (Repaid)	-	-	-	-0	0.01
Issuance of Common Stock	11.87	2.39	4.65	9.18	1.21
Other Financing Activities	-0.74	-	-0.04	-0.78	-0.02
Financing Cash Flow	11.12	2.39	4.61	8.4	1.2
Foreign Exchange Rate Adjustments	-0.03	0	-	-	-
Net Cash Flow	5.91	-1.65	-2.02	2.89	1.15
Cash Interest Paid	0	-	-	-	-
Levered Free Cash Flow	-	-2.07	-3.42	-2.61	-
Unlevered Free Cash Flow	-	-1.58	-3.42	-2.61	-
Change in Net Working Capital	-	-1.2	-1.22	0.46	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.